Last reviewed · How we verify
Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose (variant-adapted-bnt162b2-omicron-kp-2-10-microgram-dose)
At a glance
| Generic name | variant-adapted-bnt162b2-omicron-kp-2-10-microgram-dose |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: